



March 22, 2021

**Confidential & Proprietary Information
By FedEx**

U.S. NRC Region III
2443 Warrenville Road
Suite 210
Lisle, Illinois 60532-4352

Re: Notice of Transaction Impacting RAM Licenses Held by PharmaLogic Entities

To whomever it may concern:

PharmaLogic Holdings Corp. (“**PharmaLogic**”) and Webster Equity Partners, LLC (“**Webster Capital**”) (collectively, the “**Parties**”) hereby notify the U.S. Nuclear Regulatory Commission and associated Agreement States (collectively, the “**NRC/AS**”) of a planned equity transaction affecting the radioactive materials licenses (the “**Licenses**”) held directly by the PharmaLogic operating entities listed in Attachment C. Immediately prior to the contemplated transaction, Webster Capital will indirectly control 76.55% of PharmaLogic through two Webster Capital managed investment funds, Webster Capital III, L.P. (“**Webster Capital III**”) and Webster Capital IV, L.P. (“**Webster Capital IV**”, and together with Webster Capital III, the “**Webster Funds**”). Webster Capital III is transferring its indirect interests in PharmaLogic to an affiliated entity, (the “**Transaction**”) Webster Equity Partners III-A, L.P. (“**Webster Capital III-A**”) which will be a new ultimate holding company over PharmaLogic, but Webster Capital will still be in control of the Webster Funds and Webster III-A. Webster Capital’s right to exercise authority over PharmaLogic will not change as a result of the Transaction. Accordingly, the Parties do not believe that license transfer approval of the Transaction is required, but nonetheless provide the relevant information herein for the NRC/AS to evaluate a change of control should it be necessary.

The Licenses relevant to NRC Region III are listed below:

RAM - NRC Region III	NRC	Hot Shots Nuclear Medicine, LLC (Lansing)	21-26597-01MD
	NRC	Hot Shots Nuclear Medicine, LLC (Marquette)	21-32812-01MD
	NRC	Mid-America Isotopes, Inc.	24-26241-01MD
	NRC	PharmaLogic MI, L.L.C.	21-32190-01MD
	NRC	Essential Isotopes	24-32762-02
	NRC	Essential Isotopes	24-32762-01MD

PharmaLogic
433 Plaza Real, Suite 275 • Boca Raton, FL 33432
Phone: 561-416-0085 • Website: www.radiopharmacy.com

March 22, 2021

Page 2

This Transaction will have no impact on PharmaLogic's licensed activities. Post-Transaction, the day-to-day operations under PharmaLogic will remain unchanged. The PharmaLogic operating entities will continue to conduct operations under the Licenses at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

While the Parties do not believe that approval of this Transaction is required, should any NRC/AS disagree, the Parties respectfully request expedited review and approval by March 27, 2021, or sooner, if possible, and prompt posting of this application for the 30-day comment period so this Transaction can occur as scheduled. Attachment A provides the information needed to evaluate whether a license transfer is occurring. Attachment B presents pre- and post-transaction organizational charts.

If you have any questions or comments pertaining to this submission, please contact PharmaLogic's counsel for nuclear regulatory matters, Kevin Madagan, at Reed Smith LLP (202-414-9236, kmadagan@reedsmith.com).

Enclosures: Attachment A, Responses to Questions set forth in Appendix E to NUREG-1556 for Evaluating a Change of Control

Attachment B, Simplified Organizational Chart Describing the Transaction

Attachment C, PharmaLogic NRC/AS License List

cc: Kevin Madagan, Reed Smith LLP


I declare under penalty of perjury under the laws of the United States of America that to the best of my knowledge the information contained in this submittal pertaining to PharmaLogic Holdings Corp. and its companies is true and correct.

Executed on 3/19/2021



Steve Chilinski, Chief Executive Officer
PharmaLogic Holdings Corp.

I declare under penalty of perjury under the laws of the United States of America that to the best of my knowledge the information contained in this submittal pertaining to Webster Equity Partners, LLC is true and correct.

Executed on  3/19/2021

David Malm, Founding Member
Webster Equity Partners, LLC.

Attachment A – License Transfer Application

This information is submitted consistent with Chapter 5 (Change of Control) and Appendix E (Information Needed for Transfer of Control Application) of NUREG-1556, Vol. 15, Rev. 1, Consolidated Guidance about Materials Licenses: Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses.

- 1. Describe any planned changes in the organization, including but not limited to, transfer of stocks or assets and mergers, change in members on Board of Directors, etc. Provide the new licensee name, mailing address, and contact information, including phone numbers. Clearly identify when the amendment request is due to a name change only.**

Various subsidiary operating entities of PharmaLogic (collectively, the “Licensees”) hold the NRC/AS licenses listed in Attachment C. The Licensees will be indirectly controlled by 76.55% by investment funds managed by Webster Capital. PharmaLogic is the direct parent company over the Licensees.

Webster Capital plans to transfer its interests in PharmaLogic to an affiliated entity that will become a new ultimate holding company over the Licensees, called “Webster Capital III-A,” but Webster Capital would still be in control of Webster Capital III, Webster Capital IV and Webster Capital III-A (the “**Transaction**”). In other words, the right to exercise authority over PharmaLogic will not change as a result of the Transaction.

PharmaLogic would also remain the direct parent company over the Licensees. Accordingly, the Parties do not believe that NRC license transfer approval of the Transaction is required. Attachment B presents a simplified pre- and post-Transaction organizational chart.

This Transaction, will have no impact on the Licensees’ licensed activities. Post-Transaction, the day-to-day operations under PharmaLogic and the Licensees will remain unchanged. The Licensees will continue conduct operations at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

- 2. Describe any changes in personnel or duties that relate to the licensed programs. Include training and experience for new personnel and any changes in the training program.**

There are no such changes as a result of the Transaction. Post-Transaction, the day-to-day operations under PharmaLogic and the Licensees will remain unchanged. The Licensees will continue conduct operations at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

- 3. Describe any changes in the location, facilities, equipment, radiation safety programs, use, possession, waste management, or other procedures that relate to the licensed program.**

There are no such changes as a result of the Transaction. Post-Transaction, the day-to-day operations under PharmaLogic and the Licensees will remain unchanged. The Licensees will continue conduct operations at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

- 4. Describe the status of the licensees' facilities, equipment, and radiation safety program, including any known contamination and whether decontamination will occur prior to transfer. Include the status of calibrations, leak tests, area surveys, wipe tests, training, quality control, and related records.**

The status of the Licensees' facilities, equipment, and radiation safety program will not change in connection with the Transaction. The Licensees will continue conduct operations at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

- 5. If current decommissioning funding plans (DFP) will be changed as a result of the transfer, the revised DFP should be submitted. If other financial assurance documents will be changed as a result of the transfer, confirm that all financial assurance instruments associated with the license will be held in the transferee's name before the license is transferred, and as required by 10 CFR 30.35(1), the licensee must, within 30 days, submit financial instruments reflecting such changes.**

There are no such changes as a result of the Transaction.

- 6. Confirm that all records concerning the safe and effective decommissioning of the facility will be transferred to the transferee or to NRC, as appropriate. These records include documentation of surveys of ambient radiation levels and fixed and/or removable contamination, including methods and sensitivity.**

All such records will remain with the same Radiation Safety Officers and in the same locations. The Licensees will continue conduct operations at the same respective locations, using the same materials, facilities, procedures, and personnel as before, including the same Radiation Safety Officers.

- 7. Confirm that both transferor and transferee agree to transferring control of the licensed material and activity, and the conditions of transfer, and that the transferee has been made aware of any open inspection items and its responsibility for possible resulting enforcement actions.**

There are no such changes as a result of the Transaction.


- 8. Confirm that the transferee will abide by all constraints, conditions, requirements, representations, and commitments of the transferor or that the transferee will submit a complete description of the proposed licensed program.**

The Parties will abide by all such current constraints, requirements, and commitments under the Licenses.


- 9. The transferee, in the case of fuel cycle facilities, shall provide documentation showing that it is financially qualified to conduct normal operations. The information can be in the form of income statements and balance sheet forecasts.**

This question is not applicable for these Licenses.

Attachment B – PharmaLogic Organizational Chart



PharmaLogic Organizational Chart (Post-Transaction)



Attachment C – Licenses Held by PharmaLogic Entities

License Type	State	Facility	License Number
RAM - Agreement States	Colorado	Pharmalogic Colorado, LLC	CO 1296-01
	Illinois	Hot Shots Nuclear Medicine, LLC (Peoria)	IL-01874-01
		Hot Shots Nuclear Medicine, LLC (Rockford)	IL-01874-01
	Iowa	Hot Shots Nuclear Medicine, LLC (Cedar Rapids)	0289-1-57-NP
		Hot Shots Nuclear Medicine, LLC (Davenport)	0207-1-82-NP
	Kentucky	Invivo Molecular Imaging	202-417-29
		Radiopharmacy of Paducah, Inc.	202-221-32
	Maine	PharmaLogic ME, Inc.	11713-01MD
	New Jersey	Nuclear Diagnostic Products, Inc.	457798-RAD200002
		Nuclear Diagnostic Products of Philadelphia, Inc.	455467-RAD180001
	New York	Nuclear Diagnostic Products of New York Inc.	C3115
		PharmaLogic Syracuse, LLC (Albany)	C3231
		PharmaLogic Syracuse, LLC (Syracuse)	C2935
		PharmaLogic Syracuse, LLC (Syracuse)	C3126
	Pennsylvania	PharmaLogic Penn LTD.	PA0730
	South Carolina	Diagnostic Laboratories, LLC	940
	Tennessee	Precision Nuclear, LLC	R-90046-A26
		Clinical Pharmacy Services, Inc.	R-09933-F26
		Diagnostic Laboratories, LLC	R-90053-L30
	Texas	Rio Grande Valley Isotopes, L.L.C.	L06202
	Vermont	PharmaLogic Ltd. Vermont	44-30124-01MD
	Virginia	Diagnostic Laboratories, LLC	000-571-1
		Precision Nuclear of Virginia, LLC	161-479-1
		Precision Nuclear of Carilion	770-648-1
		Blue Ridge Isotopes, LLC	161-449-1
	Wisconsin	Wisconsin Medical Radiopharmacy, LLC.	079-1366-01
NRC – Region I	NRC	Lantheus MI Radiopharmaceuticals, Inc.	52-25361-02
	NRC	Lantheus MI Radiopharmaceuticals, Inc.	52-25361-01-MD
	NRC	Diagnostic Laboratories, LLC	41-31476-01
	NRC	PharmaLogic WV Ltd. (Bridgeport)	47-25275-01MD
	NRC	Radiopharmacy Inc. (Evansville)	13-26246-01MD
	NRC	PharmaLogic WV Ltd. (Huntington)	47-25375-01MD
RAM - NRC Region III	NRC	Hot Shots Nuclear Medicine, LLC (Lansing)	21-26597-01MD
	NRC	Hot Shots Nuclear Medicine, LLC (Marquette)	21-32812-01MD
	NRC	Mid-America Isotopes, Inc.	24-26241-01MD
	NRC	PharmaLogic MI, L.L.C.	21-32190-01MD
	NRC	Essential Isotopes	24-32762-02
	NRC	Essential Isotopes	24-32762-01MD
RAM - NRC Region IV	NRC	PharmaLogic MT, Inc.	09-29398-01MD
	NRC	PharmaLogic WY, Inc.	49-27629-01MD

RECEIVED MAR 24 2021

ORIGIN ID: JRBA (212) 549-0257
ANNE MAGEE
REED SMITH LLP
599 LEXINGTON AVENUE

SHIP DATE: 22MAR21
ACTWGT: 1.00 LB
CAD: 103086546/NET4340

NEW YORK CITY, NY 10022
UNITED STATES US

BILL SENDER

TO U.S. NRC REGION III

2443 WARRENVILLE ROAD
SUITE 210
LISLE IL 60532


(646) 879-1423

REF: 969875.20176

INV.
P.O. ENTER ELITE # HERE

DEPT.

56DUBAC39FE4A




TUE - 23 MAR 10:30A
PRIORITY OVERNIGHT

TRK# 7732 2862 9443
0201

XH DPAA

60532
IL-US ORD



After printing this label:

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.